Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway

Fig. 6

Inhibition SIRT7 enhances doxorubicin toxicity. a HepG2 and Huh7.5 cells were transfected with Flag-SIRT7 for 24 h and treated with doxorubicin (0.75 μM) for 36 h. Protein levels were evaluated by western blot. b and c HepG2 and Huh7.5 cells were transfected with siSIRT7 or shSIRT7 as indicated for 72 h, cells were left untreated (UT) or treated with doxorubicin (0.1 μM) for 36 h. Protein levels were evaluated by western blot (b) and cell death were evaluated by TUNEL assay (c). *P < 0.05, **P < 0.01, ***P < 0.001 vs UT, Student’s t-test. The inset shows SIRT7 knockdown efficiency in HepG2 cells. d Concentration responsiveness curves of doxorubicin in Huh7.5 and HepG2 cells were untreated (Control) or treated with siSIRT7 for 72 h, followed by doxorubicin treatment in the absence or presence of RGFP966 (10 μM) for 36 h. Determination of the inhibitory concentration (IC50) values were obtained by log-linear interpolation of data points. Dot line indicates IC50 values of doxorubicin in various conditions. e Tumor growth curves of tumor bearing NSG mice were received Vehicle, RGFP966 (RGFP, 10 mg/kg), doxorubicin (2 mg/kg) or combination (DOX + RGFP) treatment for 2 weeks. f Western lot analysis of protein levels in tumor that receiving different treatment. g IHC staining analysis in tumors as in (e). Data are representative of three independent experiments. Graphs show mean ± SEM

Back to article page